Objective: To test the safety of spinal cord transplantation of human stem cells in patients
with amyotrophic lateral sclerosis (ALS) with escalating doses and expansion of the trial to …

Objective The US Food and Drug Administration–approved trial,“A Phase 1, Open‐Label,
First‐in‐Human, Feasibility and Safety Study of Human Spinal Cord‐Derived Neural Stem …

Abstract Objective The first US Food and Drug Administration–approved clinical trial to treat
amyotrophic lateral sclerosis (ALS) with neural stem cell–based therapy is in progress. The …

Effective treatments are urgently needed for amyotrophic lateral sclerosis (ALS), a fatal
neurodegenerative disease characterized by the loss of motor neurons. In 2009, the FDA …

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder in which
the loss of upper and lower motor neurons produces progressive weakness and eventually …

The main objective of this phase I trial was to assess the feasibility and safety of
microtransplanting human neural stem cell (hNSC) lines into the spinal cord of patients with …

BACKGROUND: The first US Food and Drug Administration approved clinical trial for a stem
cell-based treatment of amyotrophic lateral sclerosis has now been completed. OBJECTIVE …

BACKGROUND: No United States-based clinical trials have attempted delivery of biological
therapies directly to the spinal cord for treatment of amyotrophic lateral sclerosis (ALS) …

Transplantation of several types of stem cells (SC) for the treatment of amyotrophic lateral
sclerosis (ALS) has been evaluated in numerous Phase I/II clinical trials with inconclusive …

Advances in stem cell biology have generated intense interest in the prospect of
transplanting stem cells into the nervous system for the treatment of neurodegenerative …